Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10806)
All Articles published online
|
Sep 14, 2011 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i34/3881.htm |
| Number | Citing Articles |
| 1 |
Mohit Mittal, Ke-Qin Hu. Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection. Current Hepatology Reports 2017; 16(2): 90 doi: 10.1007/s11901-017-0339-9
|
| 2 |
Albert J Czaja. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opinion on Pharmacotherapy 2014; 15(12): 1715 doi: 10.1517/14656566.2014.931938
|
| 3 |
Anil Arora, Anil C. Anand, Ashish Kumar, Shivaram P. Singh, Rakesh Aggarwal, Radha K. Dhiman, Shyam Aggarwal, Seema Alam, Pradeep Bhaumik, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Ashok Kumar, Manoj Kumar, Kaushal Madan, Natarajan Murugan, Aabha Nagral, Amarender S. Puri, Padaki N. Rao, Neeraj Saraf, Vivek A. Saraswat, Sanjeev Sehgal, Praveen Sharma, Koticherry T. Shenoy, Manav Wadhawan. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. Journal of Clinical and Experimental Hepatology 2018; 8(4): 403 doi: 10.1016/j.jceh.2018.06.010
|
| 4 |
Ioana Agache, Catalina Cojanu, Alexandru Laculiceanu, Liliana Rogozea. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy, Asthma & Immunology Research 2020; 12(1): 24 doi: 10.4168/aair.2020.12.1.24
|
| 5 |
Jutta Auberger, Richard Greil. Management of immunosuppression in the treatment of chronic lymphocytic leukemia. memo - Magazine of European Medical Oncology 2013; 6(1): 37 doi: 10.1007/s12254-013-0072-1
|
| 6 |
Sema Sezgin Göksu, Şerife Bilal, Hasan Şenol Coşkun. Hepatitis B reactivation related to everolimus. World Journal of Hepatology 2013; 5(1): 43-45 doi: 10.4254/wjh.v5.i1.43
|
| 7 |
A. Fylaktou, M. Daoudaki, V. Dimou, E. Sianou, D. Papaventsis, I. Mavrovouniotis, I. Fouzas, V. Papanikolaou. Hepatitis B Reactivation in a Renal Transplant Patient Due to a Surface Antigen Mutant Strain: A Case Report. Transplantation Proceedings 2012; 44(9): 2773 doi: 10.1016/j.transproceed.2012.09.011
|
| 8 |
Evangelista Sagnelli, Mariantonietta Pisaturo, Salvatore Martini, Pietro Filippini, Caterina Sagnelli, Nicola Coppola. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World Journal of Hepatology 2014; 6(6): 384-393 doi: 10.4254/wjh.v6.i6.384
|
| 9 |
Hwi Young Kim, Won Kim. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World Journal of Gastroenterology 2014; 20(40): 14581-14588 doi: 10.3748/wjg.v20.i40.14581
|
| 10 |
Nazan Tuna, Oguz Karabay. Hepatitis B reactivation and timing for prophylaxis. World Journal of Gastroenterology 2015; 21(7): 2263-2264 doi: 10.3748/wjg.v21.i7.2263
|
| 11 |
Kiran Motaparthi, Vladimir Stanisic, Abby S. Van Voorhees, Mark G. Lebwohl, Sylvia Hsu. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti–tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. Journal of the American Academy of Dermatology 2014; 70(1): 178 doi: 10.1016/j.jaad.2013.08.049
|
| 12 |
Ying-Ming Chiu, Mei-Shu Lai, K. Arnold Chan. Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study. Arthritis Research & Therapy 2017; 19(1) doi: 10.1186/s13075-017-1413-y
|
| 13 |
Aditi Sinha, Arvind Bagga. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nature Reviews Nephrology 2013; 9(3): 154 doi: 10.1038/nrneph.2012.289
|
| 14 |
Eileen P. Scully, Michael Klompas, Elizabeth A. Morgan, Amy Leigh Miller, Joseph Loscalzo. Waiting for the Other Foot to Drop. New England Journal of Medicine 2013; 368(23): 2220 doi: 10.1056/NEJMcps1210603
|
| 15 |
Yoichi Iwafuchi, Yuko Oyama, Takashi Morita, Akira Kamimura, Shigeru Miyazaki, Ichiei Narita. De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids. CEN Case Reports 2013; 2(1): 28 doi: 10.1007/s13730-012-0033-2
|
| 16 |
Vicki A. Morrison. Immunosuppression Associated With Novel Chemotherapy Agents and Monoclonal Antibodies. Clinical Infectious Diseases 2014; 59(suppl_5): S360 doi: 10.1093/cid/ciu592
|
| 17 |
Artsiom Klimko, Georgiana A Toma, Nona Bejinariu, Silviu-Mihai Secareanu, Iuliana Andreiana. Acute Kidney Injury in a Patient With Cryoglobulinemia Secondary to Hepatic Mucosa-Associated Lymphoid Tissue Lymphoma: Case Report and Literature Review. Cureus 2020; doi: 10.7759/cureus.10451
|
| 18 |
Jonathan Skupsky, Ke-Qin Hu. Current hepatitis B treatment guidelines and future research directions. Frontiers of Medicine 2014; 8(2): 145 doi: 10.1007/s11684-014-0335-1
|
| 19 |
J. Koskinas, M. Tampaki, P.P. Doumba, E. Rallis. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. British Journal of Dermatology 2013; 168(3): 679 doi: 10.1111/bjd.12120
|
| 20 |
Laurence Beck, Andrew S. Bomback, Michael J. Choi, Larry B. Holzman, Carol Langford, Laura H. Mariani, Michael J. Somers, Howard Trachtman, Meryl Waldman. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis. American Journal of Kidney Diseases 2013; 62(3): 403 doi: 10.1053/j.ajkd.2013.06.002
|
| 21 |
V. Selvarajah, A. J. Montano‐Loza, A. J. Czaja. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Alimentary Pharmacology & Therapeutics 2012; 36(8): 691 doi: 10.1111/apt.12042
|
| 22 |
Jing Fang, Wenge Li, Min Tan, Wen Chen, Cong Zhang, Wenbo Wang, Qianqian Xu, Xinzhen Guo. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. International Urology and Nephrology 2018; 50(9): 1653 doi: 10.1007/s11255-018-1867-0
|
| 23 |
Marissa Sjoblom, Haithem Chtioui, Montserrat Fraga, Gregoire Stalder, Francesco Grandoni, Sabine Blum. Hepatitis B reactivation during ruxolitinib treatment. Annals of Hematology 2022; 101(9): 2081 doi: 10.1007/s00277-022-04851-6
|
| 24 |
B. Guruprasad, S. Kavitha, B.S. Aruna Kumari, B.R. Vijaykumar, B.G. Sumati, Sinha Mahua, L. Appaji, R.S. Jayshree. Risk of hepatitis B infection in pediatric acute lymphoblastic leukemia in a tertiary care center from South India. Pediatric Blood & Cancer 2014; 61(9): 1616 doi: 10.1002/pbc.25065
|
| 25 |
Qixia Wang, Paul Klenerman, Nasser Semmo. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017; 2(2): 123 doi: 10.1016/S2468-1253(16)30076-0
|
| 26 |
Benjamin P. Davis, Zuhair K. Ballas. Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology 2017; 139(5): 1445 doi: 10.1016/j.jaci.2017.02.013
|
| 27 |
C. Sagnelli, M. Macera, M. Pisaturo, R. Zampino, M. Coppola, E. Sagnelli. Occult HBV infection in the oncohematological setting. Infection 2016; 44(5): 575 doi: 10.1007/s15010-016-0891-1
|
| 28 |
C. Nardis. Latent Virus Reactivation Risk and Biological Drugs: Chronic Inflammatory and Immune-Mediated Disorders. International Journal of Immunopathology and Pharmacology 2013; 26(4): 983 doi: 10.1177/039463201302600419
|
| 29 |
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye, Michael Boyle. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00035-19
|
| 30 |
Seok Jin Kim, Chiun Hsu, Yu-Qin Song, Kevin Tay, Xiao-Nan Hong, Junning Cao, Jin Seok Kim, Hyeon Seok Eom, Joon Hyeok Lee, Jun Zhu, Kian-Meng Chang, Arry Harryanto Reksodiputro, Daryl Tan, Yeow Tee Goh, Jejung Lee, Tanin Intragumtornchai, Wee-Joo Chng, Ann-Lii Cheng, Soon Thye Lim, Cheolwon Suh, Yok-Lam Kwong, Won Seog Kim. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer 2013; 49(16): 3486 doi: 10.1016/j.ejca.2013.07.006
|
| 31 |
Shaheen H. Ensanyat, Adam J. Luber, Jacob O. Levitt. Successful Treatment of Plaque Psoriasis with Ustekinumab in a Patient with Chronic Hepatitis B and Latent Tuberculosis. Psoriasis Forum 2013; (2): 80 doi: 10.1177/247553031319a00205
|
| 32 |
Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, Alessio Gambardella, Claudio Guarneri, Paolo Romita, Annunziata Raimondo, Francesco Loconsole, Gabriella Fabbrocini. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clinical Drug Investigation 2022; 42(6): 525 doi: 10.1007/s40261-022-01163-5
|
| 33 |
Ahmad AlEnizi, Khaled AlSaeid, Adel Alawadhi, Eiman Hasan, Entesar H. Husain, Ahmad AlFadhli, Aqeel Ghanem, Fatemah Abutiban, Yaser Ali, Adeeba Al-Herz, Khuloud Mohammed, Waleed Alkandari, Ali Aldei, Hebah Alhajeri, Ahmad Dehrab, Sawsan Hayat. Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases. International Journal of Rheumatology 2018; 2018: 1 doi: 10.1155/2018/5217461
|
| 34 |
Justine Mill, Ian C Lawrance. Preventing infective complications in inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(29): 9691-9698 doi: 10.3748/wjg.v20.i29.9691
|
| 35 |
Gilda Tonziello, Marintonietta Pisaturo, Antonello Sica, Maria Giovanna Ferrara, Caterina Sagnelli, Giuseppe Pasquale, Evangelista Sagnelli, Salvatore Guastafierro, Nicola Coppola. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013; 41(1): 225 doi: 10.1007/s15010-012-0305-y
|
| 36 |
Pilar López-Serrano, Elsa de la Fuente Briongos, Elisa Carrera Alonso, Jose Lázaro Pérez-Calle, Conrado Fernández Rodríguez. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World Journal of Hepatology 2015; 7(3): 539-547 doi: 10.4254/wjh.v7.i3.539
|
| 37 |
Karen Ly, Mary Patricia Smith, Quinn Thibodeaux, Kristen Beck, Tina Bhutani, Wilson Liao. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Reports 2019; 5(7): 624 doi: 10.1016/j.jdcr.2019.05.007
|
| 38 |
Shashi A. Gujar, Patricia M. Mulrooney-Cousins, Tomasz I. Michalak. Repeated Exposure to Trace Amounts of Woodchuck Hepadnavirus Induces Molecularly Evident Infection and Virus-Specific T Cell Response in the Absence of Serological Infection Markers and Hepatitis. Journal of Virology 2013; 87(2): 1035 doi: 10.1128/JVI.01363-12
|